Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides.

Silo Pharma Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Patent Office issued a notice of allowance for its technology/method patent covering an isolated homing peptide and how it can help deliver drugs to the central nervous system (CNS).

“We are pleased to have been granted this patent by the United States Patent and Trademark Office for our novel homing peptide,” said CEO Eric Weisblum in a press release announcing the USPTO’s decision. “We will continue to expand our intellectual property portfolio related to markets where our novel therapeutics can be applied.”

Click here to receive investor information and corporate updates

After filing a provisional patent application, an examiner from the USPTO determines if an invention qualifies for a patent. Once the examiner decides to grant the patent, they issue a notice of allowance, which means that the patent is valid after paying registration fees.

The company’s efforts to secure patents are the cornerstone of its strategy to develop and license therapeutics. Unlike competitors administering generic psychedelics, the company’s patented technology could improve safety and efficacy while guaranteeing market exclusivity.

Bringing Products to Market

Silo Pharma initially entered into an exclusive agreement with the University of Maryland-Baltimore to license its patented homing peptides targeting rheumatoid arthritis (RA)—a market that’s projected to reach nearly $63 billion by 2027. 

Management believes that the same technologies could also address a much larger market for central nervous system therapeutics. According to Global Industry Analysts, the global CNS therapeutics market could reach more than $132 billion by 2024.

The homing peptides work by helping conventional therapeutics better target diseased tissue. Through better targeting, the company could enhance efficacy and minimize toxicity by potentially reducing the amount of active ingredients needed to achieve the same outcome and opening the door to safely delivering more active ingredients.

The company believes that the same homing peptide approach could improve the safety and efficacy of psychedelic treatments. In August 2020, the company also filed three provisional patent applications covering the central nervous system delivery of psilocybin and NSAIDs, as well as a fourth provisional patent covering the use of psilocybin for cancer treatment.

Visit the company’s website to learn more about its pipeline and IP portfolio.

Presently, the company is working with researchers to build out these technologies and pave the way for clinical trials. The goal is to target FDA designations that would expedite clinical trials while extending exclusivity periods, creating more value than conventional drugs.

Looking to the Future

Silo Pharma Inc. (OTCQB: SILO) has numerous upcoming catalysts that investors should watch over the coming months. For example, the company has several ongoing preclinical and clinical trials, such as its Phase 2B study of psychedelics for treating Parkinson’s disease.

As it secures patents, the company can license these therapeutics to big pharma companies that can take them through Phase II and III clinical trials. Management’s long-term goal is to maintain a capital-efficient strategy that builds long-term, high-margin royalty income.

The company also owns one million shares of DatChat, Inc. (NASDAQ: DATS)—a privacy-focused communication company that recently went public on the NASDAQ. With a share price of around $3.70, the company’s position is worth around $3.6 million, subject to restrictions and other conditions on their holdings.

To learn more, visit the company’s website or download their investor presentation.

Click here to receive investor information and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease that causes painful swelling in joints in the hands, wrists, and knees. While medications can slow the disease and prevent joint deformity, there is no cure for the condition, and many millions still suffer from it.

Silo Pharma Inc. (OTCQB: SILO) is a development-stage biopharmaceutical company leveraging homing peptides to improve cellular targeting. In RA, the company hopes to deliver dexamethasone via peptide-guided liposomes to enhance its efficacy and toxicity profile.

Let’s take a look at the company’s recent move toward commercialization, as well as how its underlying technology could pave the way for expansion into other markets.

Moving Toward Commercialization

Silo Pharma extended its exclusive option agreement with the University of Maryland-Baltimore earlier this month to explore a novel intervention, generally known as “joint-homing peptides for use in the investigation and treatment of arthritogenic processes,” which has shown a lot of promise in early-stage research in targeting specific cells.

The company subsequently entered into a Scientific Research Agreement with the university to evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via its peptide-guided liposomes. By selecting an FDA-approved drug, the researchers can focus on delivering the maximum possible dose to specific areas.

Click here to receive investor information and corporate updates

“This agreement is a milestone for the company as we add a significant addressable market for our therapeutic approach,” said Chairman and CEO Eric Weisblum in a press release. “This study will … help establish our hypothesis that we can not only target parts of the body but can lower toxicity and help keep healthy organs unexposed to therapeutics.”

Expansion into Psychedelics

Silo Pharma believes that the same peptide-guided liposomes are adaptable to other drugs because liposomes can be loaded with both hydrophobic and hydrophilic drugs, permitting combination drug therapies. These drugs include emerging psychedelic medicines, such as ketamine and psilocybin for mental health conditions.

In addition to their work with the University of Maryland-Baltimore, the company is working with the University of California-San Francisco via a Scientific Research Agreement to study psilocybin as an anti-inflammatory agent in Parkinson’s disease and bipolar disorder. The study is taking place via the Translational Psychedelic Research Program. 

The company is also waiting on a Netherlands-based investigator-led study of psilocybin to treat Parkinson’s disease, submitted for ethics board review in May, and entered into a joint venture with Zylo Therapeutics to develop a transdermal ketamine therapeutic, among other efforts in the psychedelics space.

Looking Ahead

Silo Pharma Inc. (OTCQB: SILO) has made significant progress in advancing its homing peptide-based technology into rheumatoid arthritis and other markets. Leveraging the same technology platform, the company hopes to target a wide range of different drugs, enabling more efficacy and an improved patient safety profile.

Click here to receive investor information and corporate updates

The company also continues to build and monetize its intellectual property through licensing agreements, such as its agreement with Alkido Pharma Inc. (NASDAQ: AIKI) earlier this year. Under these agreements, the company could receive upfront cash payments and ongoing royalty payments on products developed with the technology.

For more information about Silo Pharma, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.